Clinical Research Directory
Browse clinical research sites, groups, and studies.
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
Sponsor: ARS Pharmaceuticals, Inc.
Summary
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
Official title: A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma
Key Details
Gender
All
Age Range
12 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2022-07-28
Completion Date
2024-02-02
Last Updated
2026-07-14
Healthy Volunteers
No
Conditions
Interventions
ARS-1 1 mg
ARS-1 1 mg
Albuterol MDI
180 mcg
Placebo
Placebo
ARS-1 2mg
ARS-1 2mg
Locations (4)
University of South Florida
Tampa, Florida, United States
Institute for Asthma and Allergy
Chevy Chase, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States